Comments on: In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug

Comments on: In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug https://medcitynews.com/2025/08/ionis-dawnzera-fda-approval-hereditary-angioedema-hae-prophylaxis-donidalorsen-ions/ Healthcare technology news, life science current events Wed, 27 Aug 2025 19:01:44 +0000 hourly 1 https://wordpress.org/?v=6.8.5